Literature DB >> 27514468

The Future of Precision Medicine in Oncology.

Lori M Millner1, Lindsay N Strotman2.   

Abstract

Precision medicine in oncology focuses on identifying which therapies are most effective for each patient based on genetic characterization of the cancer. Traditional chemotherapy is cytotoxic and destroys all cells that are rapidly dividing. The foundation of precision medicine is targeted therapies and selecting patients who will benefit most from these therapies. One of the newest aspects of precision medicine is liquid biopsy. A liquid biopsy includes analysis of circulating tumor cells, cell-free nucleic acid, or exosomes obtained from a peripheral blood draw. These can be studied individually or in combination and collected serially, providing real-time information as a patient's cancer changes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell-free nucleic acid (cfNA); Circulating tumor cell (CTC); Exosomes; Extracellular vesicle (EV); Liquid biopsy; Targeted therapy

Mesh:

Year:  2016        PMID: 27514468     DOI: 10.1016/j.cll.2016.05.003

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  13 in total

1.  Characterization of Patients Who Present With Insomnia: Is There Room for a Symptom Cluster-Based Approach?

Authors:  Megan R Crawford; Diana A Chirinos; Toni Iurcotta; Jack D Edinger; James K Wyatt; Rachel Manber; Jason C Ong
Journal:  J Clin Sleep Med       Date:  2017-07-15       Impact factor: 4.062

Review 2.  A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies.

Authors:  Patricia A Deverka; Rick Bangs; Karma Kreizenbeck; Deborah M Delaney; Dawn L Hershman; Charles D Blanke; Scott D Ramsey
Journal:  J Natl Cancer Inst       Date:  2018-06-01       Impact factor: 13.506

Review 3.  Managing Expectations in the Transition to Proof of Concept Studies.

Authors:  Thomas Kieber-Emmons; Issam Makhoul; Angela Pennisi; Eric R Siegel; Peter D Emanuel; Bejotaloh Monzavi-Karbassi; Zenon Steplewski; J Thaddeus Beck; Laura F Hutchins
Journal:  Rev Recent Clin Trials       Date:  2017

Review 4.  Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions.

Authors:  Shyam S Mohapatra; Surinder K Batra; Srinivas Bharadwaj; Michael Bouvet; Bard Cosman; Ajay Goel; Wilma Jogunoori; Michael J Kelley; Lopa Mishra; Bibhuti Mishra; Subhra Mohapatra; Bhaumik Patel; Joseph R Pisegna; Jean-Pierre Raufman; Shuyun Rao; Hemant Roy; Maren Scheuner; Satish Singh; Gitanjali Vidyarthi; Jon White
Journal:  Dig Dis Sci       Date:  2018-03-23       Impact factor: 3.199

5.  Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
.

Authors:  Harald Hampel; Andrea Vergallo; Mohammad Afshar; Leyla Akman-Anderson; Joaquín Arenas; Norbert Benda; Richard Batrla; Karl Broich; Filippo Caraci; A Claudio Cuello; Enzo Emanuele; Marion Haberkamp; Steven J Kiddle; Alejandro Lucía; Mark Mapstone; Steven R Verdooner; Janet Woodcock; Simone Lista
Journal:  Dialogues Clin Neurosci       Date:  2019       Impact factor: 5.986

6.  Prognositic significance of P-cadherin expression in breast cancer: Protocol for a meta-analysis.

Authors:  Yupeng Xi; Xiwen Zhang; Zizhen Yang; Xing Zhang; Qiujun Guo; Zhenhua Zhang; Shuntai Chen; Honggang Zheng; Baojin Hua
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

7.  Fishing for cures: The alLURE of using zebrafish to develop precision oncology therapies.

Authors:  Matteo Astone; Erin N Dankert; Sk Kayum Alam; Luke H Hoeppner
Journal:  NPJ Precis Oncol       Date:  2017-11-27

8.  Precision oncology using a limited number of cells: optimization of whole genome amplification products for sequencing applications.

Authors:  Shonan Sho; Colin M Court; Paul Winograd; Sangjun Lee; Shuang Hou; Thomas G Graeber; Hsian-Rong Tseng; James S Tomlinson
Journal:  BMC Cancer       Date:  2017-07-01       Impact factor: 4.638

9.  Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.

Authors:  D Mandelker; M Donoghue; S Talukdar; C Bandlamudi; P Srinivasan; M Vivek; S Jezdic; H Hanson; K Snape; A Kulkarni; L Hawkes; J-Y Douillard; S E Wallace; E Rial-Sebbag; F Meric-Bersntam; A George; D Chubb; C Loveday; M Ladanyi; M F Berger; B S Taylor; C Turnbull
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 51.769

10.  A Model of a Zebrafish Avatar for Co-Clinical Trials.

Authors:  Alice Usai; Gregorio Di Franco; Patrizia Colucci; Luca Emanuele Pollina; Enrico Vasile; Niccola Funel; Matteo Palmeri; Luciana Dente; Alfredo Falcone; Luca Morelli; Vittoria Raffa
Journal:  Cancers (Basel)       Date:  2020-03-13       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.